Menu
Search
|

Menu

Close
X

Synergy Pharmaceuticals Inc SGYP.OQ (NASDAQ Stock Exchange Global Select Market)

1.90 USD
+0.01 (+0.53%)
As of Jul 20
chart
Previous Close 1.89
Open 1.89
Volume 400,315
3m Avg Volume 845,331
Today’s High 1.91
Today’s Low 1.88
52 Week High 4.34
52 Week Low 1.42
Shares Outstanding (mil) 224.95
Market Capitalization (mil) 778.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
17
FY16
0
FY15
0
EPS (USD)
FY18
-0.146
FY17
-1.002
FY16
-1.275
FY15
-1.120
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
322.70
5.73
Price to Book (MRQ)
vs sector
17.97
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
39.13
16.84
LT Debt to Equity (MRQ)
vs sector
39.13
12.51
Return on Investment (TTM)
vs sector
-259.71
14.61
Return on Equity (TTM)
vs sector
-525.34
16.34

EXECUTIVE LEADERSHIP

Gary Jacob
Executive Chairman of the Board, Since 2017
Salary: $556,200.00
Bonus: $562,034.00
Troy Hamilton
Chief Executive Officer, Director, Since 2018
Salary: $398,513.00
Bonus: $166,725.00
Gary Gemignani
Chief Financial Officer, Executive Vice President, Since 2017
Salary: $290,417.00
Bonus: $124,375.00
Marino Garcia
Executive Vice President, Chief Strategy Officer, Since 2016
Salary: $360,833.00
Bonus: $136,800.00
Patrick Griffin
Executive Vice President, Chief Medical Officer, Since 2015
Salary: $415,300.00
Bonus: $177,413.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

420 Lexington Ave Rm 2012
NEW YORK   NY   10170-2099

Phone: +1212.2970020

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

SPONSORED STORIES